Peptide CDMO Capacity Race: $2.5 Billion Annual Investment in New Manufacturing Reaches Five-Year High

The Capacity Build-Out: Scale and Scope

The peptide contract development and manufacturing organization (CDMO) sector entered 2026 in an unprecedented expansion phase. Capital flowing into new peptide manufacturing capacity, measured across SPPS synthesis suites, purification infrastructure (HPLC), and analytical QC labs, has reached approximately $2.5-3.5 billion annually, eclipsing any prior period in the industry's history.

The catalyst is well understood: GLP-1 receptor agonists semaglutide and tirzepatide have become among the highest-revenue pharmaceutical products in history, and both require large-scale peptide synthesis that must be executed under pharmaceutical GMP conditions. The manufacturers behind these products, Novo Nordisk and Eli Lilly, have accelerated their own internal manufacturing investments while simultaneously securing long-term CDMO partnerships to guarantee supply for products projected to serve tens of millions of patients.

But GLP-1 is not the only driver. The broader pipeline of peptide therapeutics in clinical development is creating forward demand signals that justify CDMO investment well beyond GLP-1 alone:

• Oncology peptides: Peptide-drug conjugates, neoantigen vaccines, and checkpoint-modulating peptides are advancing through clinical development, with several Phase 2/3 programs requiring clinical-grade bulk manufacturing
• Metabolic peptides: Triple agonists (GLP-1/GIP/glucagon), amylin analogs, and FGF21 peptide analogs in development at multiple companies
• Cardiovascular peptides: BNP analogs, natriuretic peptide fragments, and vasopeptidase inhibitors
• CNS peptides: Neuropeptide-based approaches for neurodegenerative diseases where GLP-1 receptor expression in relevant brain regions has generated interest

The CordenPharma-AmbioPharm Combination: Market-Defining Move

The most consequential CDMO transaction in the peptide manufacturing sector in the 2025-2026 period is CordenPharma's acquisition of AmbioPharm, creating a combined entity that analysts project will control approximately 15-18% of global GMP peptide API manufacturing capacity within three years.

CordenPharma's existing position: CordenPharma (owned by ICG London-based private equity) was already one of the leading GLP-1 SPPS contract manufacturers with significant capacity at its Boulder, Colorado facility. The company had announced a EUR 1+ billion strategic investment plan that included 30,000 liters of additional SPPS capacity and 26,000 square meters of new production area.

AmbioPharm's contribution: AmbioPharm, headquartered in North Augusta, South Carolina, brings US domestic manufacturing capacity that is particularly valuable given growing interest in supply chain resilience and onshoring. AmbioPharm also has a Shanghai facility, creating an integrated East-West manufacturing footprint.

Strategic rationale: The combination creates redundant manufacturing capacity across multiple geographies, allowing the combined entity to offer customers supply chain resilience that single-site manufacturers cannot match. For pharmaceutical sponsors trying to ensure continuity of supply for billion-dollar GLP-1 products, geographic diversification is not optional.

Workforce implications: Integrations of this type typically involve workforce rationalization in overlapping functions (finance, regulatory affairs, quality systems) while expanding headcount in synthesis, purification, and analytical chemistry. The AmbioPharm acquisition is expected to create net employment growth in North Augusta, SC, as the combined entity scales capacity.

Scale Engineering: The 1,000-5,000 Liter Challenge

Traditional solid-phase peptide synthesis (SPPS) for research and early clinical supply operates at scales measured in grams to kilograms. A well-equipped research SPPS facility might have synthesizers running at the 10-50 liter reactor scale.

GLP-1 commercial manufacturing operates in a fundamentally different regime. The synthesis volumes required to supply the approved GLP-1 products at current and projected market demand require SPPS reactors in the 1,000-5,000 liter range, a scale that introduces engineering challenges with no established playbook:

Solvent handling: SPPS uses large volumes of organic solvents (DMF, DCM, NMP). At commercial scale, solvent consumption runs to hundreds of thousands of liters per year for a single product. Solvent recovery, recycling, and waste management systems must be engineered from first principles at this scale.

Heat management: Exothermic coupling reactions that are trivial to manage in small reactors create significant heat generation challenges in large-scale vessels. Temperature control systems must maintain uniform conditions throughout the synthesis cycle.

Resin handling: The solid support resin used in SPPS must be uniformly mixed, washed, and handled across thousands of liters of reaction volume. Resin particle behavior (settling, aggregation, channeling) at commercial scale differs significantly from lab scale.

Purification: High-performance liquid chromatography (HPLC) purification of crude peptide at commercial scale requires industrial-scale HPLC trains with columns measured in meters of diameter. Axplora's EUR 50 million investment in large-scale HPLC capacity at its Mourenx, France site is specifically designed to address this bottleneck.

The engineering talent capable of designing, commissioning, and operating these facilities is in extremely short supply. Chemical engineers with pharmaceutical-scale SPPS manufacturing experience are among the most sought-after professionals in the life sciences labor market in 2026.

Geographic Dynamics: Onshoring vs. China Capacity

The geography of peptide CDMO capacity reflects two competing forces: the efficiency advantages of Chinese API manufacturing and the supply chain resilience arguments for domestic (US and European) production.

China's position: China remains the dominant supplier of research-grade and lower-GMP-grade peptide APIs globally, with manufacturers in Chengdu, Hangzhou, and Suzhou offering substantially lower synthesis costs than US or European CDMOs. For pharmaceutical companies sourcing starting materials and non-critical intermediates, Chinese API suppliers remain the cost-effective choice.

Onshoring momentum: For GLP-1 products specifically, the combination of supply chain concerns (China dependency risk), congressional interest in pharmaceutical supply chain security, and the strategic value of domestic manufacturing to large pharma companies has driven significant investment in US-based capacity. Both Novo Nordisk and Eli Lilly have made public commitments to expanding US manufacturing infrastructure for GLP-1 products.

The hybrid approach: Most major peptide drug sponsors in 2026 are operating dual-source strategies, qualifying both a domestic/European primary CDMO and a Chinese secondary source, to optimize cost while maintaining supply resilience.

Talent and Workforce Constraints

The capacity expansion is running directly into a talent availability constraint. The pool of professionals with deep GMP peptide synthesis manufacturing experience is small relative to the hiring demand from expanding CDMOs.

Key roles in acute shortage:

SPPS process development scientists: Scientists who can optimize synthesis protocols, troubleshoot yield issues, and scale processes from bench to commercial scale. Compensation for experienced SPPS process scientists at CDMOs is running $130,000-$180,000 in 2026, with CDMOs in competitive markets offering additional signing bonuses and retention packages.

Analytical chemistry for peptide characterization: Characterizing complex peptides (identifying impurities, verifying sequence, confirming modifications) requires specialized analytical skills in LC-MS, NMR, and peptide-specific HPLC methods. Qualified analytical chemists with peptide experience typically take 12-18 months to train from a general pharmaceutical chemistry background.

Quality systems for peptide manufacturing: GMP quality management in peptide manufacturing has unique requirements around residual solvent testing, resin qualification, and process analytical technology. Quality professionals who understand both GMP frameworks and peptide manufacturing-specific requirements are rare.

Engineering project managers: Planning and executing a 1,000-5,000 liter SPPS suite build-out from conceptual design through regulatory submission requires engineering project managers who understand pharmaceutical manufacturing design requirements. Very few project management professionals have this specific combination of skills.

CDMOs are increasingly partnering with specialized recruiters focused on life sciences manufacturing to accelerate talent acquisition, and some are establishing apprenticeship programs with local technical colleges to build pipeline for roles like synthesis technician and purification operator.

People Also Ask

Which companies are the largest peptide CDMOs in 2026?

The leading global peptide CDMOs include CordenPharma (post-AmbioPharm acquisition), Bachem (Switzerland), Polypeptide Group, Axplora, and several large Chinese CDMOs including Hybio Pharmaceutical and Shenzhen Neptunus. Novo Nordisk and Eli Lilly also operate significant captive peptide manufacturing capacity.

How much does peptide CDMO capacity expansion cost?

Commercial-scale SPPS facilities designed for GLP-1 volumes are major capital projects. A dedicated 5,000-liter SPPS manufacturing suite with associated purification and analytical infrastructure can cost $200-500 million depending on scope and location. Industry-wide, $2.5-3.5 billion annually is being invested in new capacity additions.

Why is GLP-1 manufacturing capacity so hard to build quickly?

GLP-1 manufacturing at commercial scale requires engineering approaches at the 1,000-5,000 liter SPPS reactor scale that have no established playbook, creating significant design and commissioning challenges. Additionally, the specialized talent pool (SPPS process engineers, GMP quality specialists, analytical chemists) is extremely limited, and regulatory filing and approval of new manufacturing sites adds 18-36 months to the commissioning timeline.